Shots:

• Hepion to evaluate three doses of rencofilstat (CRV431, PO, qd) in 60 presumed NASH F3 patients leveraging the HepQuant SHUNT test along with numerous NASH biomarkers collected over 4mos. The study is expected to be initiated in Q3’22
• This trial will supplement the Company’s larger 12mos. P-IIb NASH study in biopsy-proven F2/F3 NASH subjects (ASCEND-NASH) and will run concurrently with Hepion’s ongoing P-IIa clinical trial for HCC
• The incorporation of HepQuant’s SHUNT test may provide a sensitive measurement of hepatic function and will provide information on the role rencofilstat in improving the liver health in NASH subjects with advanced fibrosis

Ref: Globenewswire | Image: Hepion